Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* Patients chronically infected with hepatitis C virus (HCV) genotype 1~* HCV RNA viral load ≥10\*5\* IU/mL at screening~* Naïve or nonresponsive to the current standard of care~Key Exclusion Criteria:~* Cirrhosis~* Hepatocellular carcinoma~* Coinfection with hepatitis B virus, HIV-1 or HIV-2

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (BMS-790052, plus Peginterferon alfa-2b, Ribavirin) (Type: EXPERIMENTAL): Treatment Naive
- Arm B (BMS-790052, plus Peginterferon alfa-2b, Ribavirin) (Type: EXPERIMENTAL): Treatment Naive
- Arm C (Placebo, plus Peginterferon alfa-2b, Ribavirin) (Type: PLACEBO_COMPARATOR): Treatment Naive
- Arm D (BMS-790052, plus peginterferon alfa-2b, Ribavirin) (Type: EXPERIMENTAL): Non-Responder
- Arm E (BMS-790052, plus Peginterferon alfa-2b, Ribavirin) (Type: EXPERIMENTAL): Non-Responder

Based on this trial design, predict the completion outcome and termination type (if applicable).